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group who has any potential for possible mortality beneﬁt is those
with bilateral FM. In fact, in data that was previously published by our
group, intervention in patients with bilateral disease was associated
with improved 5 year survival (89.5% versus 52.2%).
The Ponamgi report does not provide sufﬁcient information about
the stenting procedures performed to assess whether the proceduresWe are writing to encourage reviewers and editors to establish a
higher level of data reporting for the critical determinants of vascular
stenting procedures, so that procedural outcomesmay be analyzed indi-
vidually. We disagree with the conclusion in Ponamgi et al. [1] “… all
four patients that died in our series had bilateral disease.… Thus, inter-
ventions for this patient group may afford limited symptomatic relief
without affecting mortality.”
Our experience of the past 2 decades convinces us that individual pa-
tients with bilateral ﬁbrosing mediastinitis (FM) clearly beneﬁt from
pulmonary vascular stenting, but that beneﬁt depends entirely on suc-
cessful restoration of a critical narrowing. For example, our ﬁrst pulmo-
nary vein stenting for FM in June 1996, was for a 26 year old who was
NYHA functional class IV, intermittently coughing pints of blood, with
pulmonary artery pressures equal to his systemic pressures, and who
we estimated survival of days to weeks based on prior experience. His
right lung received no pulmonary perfusion, and the conjoined left pul-
monary veins entered a short narroworiﬁce (4mm) into the left atrium.
When a 14mmstentwas placed in the oriﬁce, hewas restored to class II
functional status within a few days, and then drove large trucks profes-
sionally for most of the following 9.5 years that he survived. This expe-
rience and subsequent similar cases convinced us that some patients
with bilateral disease do receive substantial beneﬁt, even for mortality.
We agree that bilateral disease accounts for the vastmajority ofmor-
tality in FM. We tallied the number of deaths from FM of patients seen
by one of us at our institution in the last 35 years. This was not an ex-
haustive search, so we may have missed some patients. Of the 21 FM
deaths of patients known to us, 19 were patients with bilateral disease,
and 2 deaths were patients with unilateral FM. The deaths in unilateral
FM patients were preventable, at least in part, as one was a young man
who died after inappropriate surgical pneumonectomy at an outside
hospital, and the other from recurrent pneumonia in the sole functional
lung. So our experience suggests that bilateral disease accounts for
nearly all the disease relatedmortality, despite comprising theminorityyle).
land Ltd. This is an open access articloverall (20% of all FM cases). Therefore we believe that the only sub-
performedwere sufﬁcient. The use of drug eluting stents in the Ponamgi
report suggests that at least some of the stents implanted were small
caliber as there are no large caliber drug eluting stents available. In pa-
tients with FM, small caliber stents placed centrally would typically not
be able to achieve adequate diameter for pulmonary veins that often are
forced to accommodate additional pulmonary ﬂow secondary to other
sites of pulmonary vascular obstruction or occlusion.Webelieve that re-
ports of pulmonary vascular stenting in patients with FM should pro-
vide as much of the critical data as possible including diameter of
stenosis in each vessel, the pressure gradient across the stenosis, the
size and type of stent placed, the location within the vessel of stent
placement, as well as all collateral involvement of airways, arteries
and veins. Without this data it is not possible to determine whether
an effective procedure was conducted.
Our experience leads us to believe that effective pulmonary vascular
stenting for carefully selected patients clearly improves survival, as well
as symptoms, and that balloon dilation alone has no durable beneﬁt.
Further, the FM patient who has the highest possibility to beneﬁt from
stenting includes a symptomatic patientwith bilateral FMwith a critical
stenosis that is a location amenable to stent relief. We have had success
in recannulating even completely occluded vessels using large caliber
bare metal stents, with high pressure balloons for deployment. Caution
is indicated however, as untoward complications are noteworthy even
at experienced centers. For instance we reviewed the experience of a
young lady in whom an under sized stent was deployed into a pulmo-
nary vein, but embolized to a mesenteric artery.
Further Ponamgi et al. also concluded “Eight patients were identi-
ﬁed,with amean age of 41 years (24–59 years)….We describe the larg-
est reported case series of catheter-based intervention for PV stenosis in
FM “. However, we note that our series reported in 2011 (ref 21 in
Ponamgi; [2]) described the speciﬁc features of 77 stents (including
21 pulmonary veins) to treat 40 FM patients.
In summary, we believe that selected FM patients clearly beneﬁt
from pulmonary vascular stenting, especially those with bilateral dis-
ease, and that reviewers of case series should hold authors to a higher
level of description of the speciﬁcs of the anatomy and procedure, so
that outcomes can be judged by whether an effective procedure was
accomplished.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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